Boston Scientific stock fell 1.46 percent as cyber risk hit guidance

Published on 10/04/2026 at 22:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock fell to USD 42.60 on October 2, 2026, after a cyber incident put its 2026 outlook at risk. Q2 revenue rose 7.5 percent to USD 5.442 billion, while Oppenheimer cut its target from USD 85 to USD 65.

Schwarz-Weiß-Reportage: Büroangestellte treten durch Drehtüren eines Bürogebäudes — Boston Properties US1011371077 dokumentiert Angestellte beim Betreten eines klassischen amerikanischen Büroturms in der Innenstadt, Illustration mit AI erstellt.

Boston Scientific stock (ISIN US1011371077) fell 1.46 percent to USD 42.60 on the NYSE on October 2, 2026, after the company warned that a cybersecurity incident could materially affect its third-quarter and full-year results. In its September 7, 2026 filing, StockTitan reported that Boston Scientific considered its previous net sales growth and adjusted EPS guidance unlikely to be met.

Cyber incident changes the outlook

The incident began with unauthorized activity identified on August 25, 2026, and disrupted manufacturing, order processing and customer shipments. The filing said distribution had been substantially restored, sterilization facilities were operational and manufacturing had resumed at most global sites.

The next formal checkpoint is October 28, 2026, when Boston Scientific plans to discuss third-quarter results and provide an updated operational and financial outlook, according to StockTitan.

Q2 growth meets a tougher test

Before the disruption, Boston Scientific reported second-quarter 2026 revenue of USD 5.442 billion, up 7.5 percent from USD 5.061 billion a year earlier. GAAP net income attributable to common shareholders rose to USD 907 million from USD 797 million, while diluted GAAP EPS increased to USD 0.61 from USD 0.53, according to StockTitan.

Adjusted EPS was USD 0.86 in Q2 2026 versus USD 0.75 a year earlier, while the company also faced weaker momentum in WATCHMAN and competitive pressure in electrophysiology. Yahoo Finance reported that Oppenheimer lowered its target from USD 85 to USD 65 on September 21, 2026, while keeping an Outperform rating.

Analyst targets remain divided

MarketBeat lists 23 Buy ratings, 6 Hold ratings and 2 Sell ratings, producing a Moderate Buy consensus and an average target of USD 70.19. At USD 42.60, that target lies 64.8 percent above the October 2 price, according to MarketBeat.

Stock sits near its yearly low

Boston Scientific last traded at USD 42.60 on October 2, 2026, with a session range of USD 41.94 to USD 43.44. The USD 62.65 billion market capitalization and 18,283,319-share volume show the scale of the move, while the 52-week range of USD 41.94 to USD 105.65 places the stock close to its annual floor.